---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-029005"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2025-09-15T23:59:59+00:00"
generated_at: "2026-05-17T06:38:19.306307+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Monopar reports positive long-term neurological data for ALXN1840 in Wilson disease

## Summary
- Pooled efficacy from 3 trials (n=255) showed sustained neurological improvement on UWDRS Part II & III over 6 years.
- Patients crossing from standard of care to ALXN1840 showed additional neurological improvement, reversing prior worsening.
- Psychiatric improvement sustained over multiple years per Brief Psychiatric Rating Scale (BPRS).
- Safety: <1% drug-related neurological serious adverse events across >645 patient-years on ALXN1840.
- Data presented at ANA Annual Meeting; builds on hepatic efficacy data from EASL 2025.

## SEC filing metadata
- accession: 0001437749-25-029005
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2025-09-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774925029005/0001437749-25-029005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774925029005/mnpr20250912_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-029005
- JSON: https://secwatch.observer/filing/0001437749-25-029005.json
- Plain text: https://secwatch.observer/filing/0001437749-25-029005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.